TABLE 3.
Pharmacokinetic (PK) properties of Q808 after single oral administration of 6.44, 12.88 and 25.76 mg/kg.
| PK parameter | Dosage (mg) | ANOVA (p Value) | ||
|---|---|---|---|---|
| 6.44 mg/kg | 12.88 mg/kg | 25.76 mg/kg | ||
| No. | 6 | 6 | 6 | |
| Tmax, median (min–max), h | 6.00 (3.00–9.00) | 4.50 (3.00–12.00) | 4.50 (1.00–12.00) | 0.9092 |
| Cmax, mean (SD), ng/mL | 182.17 (81.81) | 406.33 (75.46) | 470.67 (77.39) | <0.0001 |
| AUC0-t, mean (SD), h*ng/mL | 3,589.17 (1028.66) | 8,754.83 (2887.94) | 10,225.00 (1384.63) | 0.0007 |
| AUC0−∞, mean (SD), h*ng/mL | 3,648.33 (1027.93) | 8,855.83 (2940.86) | 10,444.00 (1480.45) | 0.0006 |
| T1/2, mean (SD), h | 10.04 (2.592) | 9.34 (2.85) | 11.31 (2.86) | 0.4769 |
| Vd/F, mean (SD), mL | 27,650.17 (11690.63) | 20,752.00 (8171.39) | 40,109.33 (7377.86) | 0.0312 |
| CL/F, mean (SD), mL/h/kg | 1,886.83 (538.60) | 1,587.50 (488.57) | 2,517.00 (429.35) | 0.0099 |
| MRT, mean (SD), h | 17.92 (3.18) | 18.48 (4.67) | 20.22 (3.27) | 0.5581 |
Abbreviations: ANOVA, analysis of variance; SD, standard deviation; Tmax, time to peak plasma concentration; Cmax, peak plasma concentration; AUC, area under the plasma concentration; T1/2, terminal elimination halt-life; Vd/F, apparent volume of distribution; CL/F, apparent clearance; MRT, mean residence time.